Lyra Therapeutics, Inc.
LYRA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $25 | $183 | $183 | $209 |
| % Growth | -86.3% | 0% | -12.4% | – |
| Cost of Goods Sold | $100 | $200 | $0 | $0 |
| Gross Profit | -$75 | -$17 | $183 | $209 |
| % Margin | -300% | -9.3% | 100% | 100% |
| R&D Expenses | $4,047 | $5,110 | $4,876 | $6,362 |
| G&A Expenses | $0 | $3,501 | $3,263 | $3,613 |
| SG&A Expenses | $2,136 | $3,501 | $3,263 | $3,613 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$200 | $885 | $1,642 |
| Operating Expenses | $6,183 | $8,411 | $9,024 | $11,617 |
| Operating Income | -$6,258 | -$8,428 | -$8,841 | -$11,408 |
| % Margin | -25,032% | -4,605.5% | -4,831.1% | -5,458.4% |
| Other Income/Exp. Net | $277 | $993 | $298 | $435 |
| Pre-Tax Income | -$5,981 | -$7,435 | -$8,543 | -$10,973 |
| Tax Expense | $3 | $2 | $4 | $6 |
| Net Income | -$5,984 | -$7,437 | -$8,547 | -$10,979 |
| % Margin | -23,936% | -4,063.9% | -4,670.5% | -5,253.1% |
| EPS | -3.38 | -5.51 | -0.13 | -0.17 |
| % Growth | 38.7% | -4,138.5% | 23.5% | – |
| EPS Diluted | -3.38 | -5.51 | -0.13 | -0.17 |
| Weighted Avg Shares Out | 1,768 | 1,349 | 65,758 | 65,114 |
| Weighted Avg Shares Out Dil | 1,768 | 1,349 | 65,758 | 65,114 |
| Supplemental Information | – | – | – | – |
| Interest Income | $256 | $410 | $298 | $435 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $100 | $200 | $128 | $151 |
| EBITDA | -$5,881 | -$7,235 | -$7,828 | -$9,615 |
| % Margin | -23,524% | -3,953.6% | -4,277.6% | -4,600.5% |